RADNOR, Pa., July 31, 2012 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company focused on developing innovative therapeutic drugs to treat patients with serious acute-care conditions, today announced that it has received the second phase of a grant from the National Institutes of Health (NIH). This grant will continue to fund collaborative work with Dr. Doron Greenbaum, Assistant Professor of Pharmacology at the University of Pennsylvania, to support the development of defensin-mimetic antimicrobial compounds for the treatment of malaria.
